Drug Profile


Alternative Names: 20060439; AMG-386

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; Dana-Farber Cancer Institute; Gynecologic Oncology Group; Merck Sharp & Dohme; National Cancer Institute (USA); Quantum Leap Healthcare Collaborative; Roswell Park Cancer Institute; Takeda
  • Class Antibodies; Antineoplastics; Peptides; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Angiopoietin-1 inhibitors; Angiopoietin-2 inhibitors; TIE 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Discontinued Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Glioblastoma; Hepatocellular carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma

Most Recent Events

  • 31 Aug 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Inoperable/Unresctable, Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (NCT03239145)
  • 11 Aug 2017 Dana-Farber Cancer Institute plans a phase I trial for Solid tumours(Late-stage disease, Combination therapy, Inoperable/Unresctable, Metastatic disease, Second-line therapy or greater) in USA (NCT03239145)
  • 28 Jul 2017 Discontinued - Phase-I for Ovarian cancer (Combination therapy, First-line therapy) in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top